What are the long-term effects of statin therapy in patients with severe heart failure?
Long-term studies have shown that statin therapy is associated with lower mortality among patients with severe heart failure. For example, in the GISSI-HF trial, rosuvastatin was found to reduce the risk of all-cause mortality by 19% and cardiovascular death by 23% in patients with severe heart failure. Additionally, the CORONA trial found that rosuvastatin reduced the risk of all-cause mortality by 18%. Furthermore, according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III, statin therapy is recommended for primary and secondary prevention of cardiovascular events in patients with coronary artery disease, including those with heart failure. 